G1 THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.245 USD | -1.51% |
|
-12.81% | +39.51% |
Financials (USD)
| Sales 2024 * | 68.87M | Sales 2025 * | 102M | Capitalization | 225M |
|---|---|---|---|---|---|
| Net income 2024 * | -37M | Net income 2025 * | -20M | EV / Sales 2024 * | 3.27 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.21 x |
| P/E ratio 2024 * |
-6.47
x | P/E ratio 2025 * |
-15.4
x | Employees | 100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.28% |
More Fundamentals
* Assessed data
More news
Latest transcript on G1 Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -1.62% | ||
| 1 week | -12.81% | ||
| Current month | -1.50% | ||
| 1 month | +32.55% | ||
| 3 months | +32.97% | ||
| 6 months | +254.58% | ||
| Current year | +39.51% |
1 week
4.13
4.79
1 month
2.934.90
Current year
2.015.00
1 year
1.085.00
3 years
1.0824.12
5 years
1.0841.80
10 years
1.0869.57
| Managers | Title | Age | Since |
|---|---|---|---|
Jack Bailey
CEO | Chief Executive Officer | 59 | 20-03-11 |
John Umstead
DFI | Director of Finance/CFO | - | 17-12-31 |
Rajesh K. Malik
CTO | Chief Tech/Sci/R&D Officer | 65 | 14-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Glenn Muir
BRD | Director/Board Member | 65 | 15-08-31 |
Cynthia Flowers
BRD | Director/Board Member | 64 | 18-06-06 |
Norman Sharpless
FOU | Founder | 57 | 08-05-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 509 M€ | -.--% | ||
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 4.255 | -1.28% | 186 505 |
| 24-04-15 | 4.31 | -5.27% | 670,488 |
| 24-04-12 | 4.55 | -2.78% | 563,219 |
| 24-04-11 | 4.68 | +0.65% | 491,495 |
| 24-04-10 | 4.65 | -4.71% | 982,872 |
Delayed Quote Nasdaq, April 16, 2024 at 12:13 pm EDT
More quotes
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.31
USD
Average target price
8.5
USD
Spread / Average Target
+97.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +39.51% | 225M | |
| -3.01% | 103B | |
| +1.63% | 96.56B | |
| +1.72% | 22.61B | |
| -17.87% | 21.18B | |
| -4.50% | 19.07B | |
| -41.75% | 16.53B | |
| -24.84% | 14.46B | |
| +2.47% | 13.25B | |
| +21.93% | 11.1B |
- Stock Market
- Equities
- GTHX Stock
